A six-month randomized, double-blind, placebo-controlled trial at the University of Surrey found that daily NOVOS Core improved flow-mediated dilation by 2.9 percentage points, reduced pulse wave velocity by 1.18 m/s and lowered systolic blood pressure by 6.1 mmHg versus placebo in healthy adults over 40. Lipid profiles were unchanged, indicating the reduction in estimated ten-year cardiovascular risk was driven by blood pressure and vessel function rather than cholesterol. The trial included 61 randomized participants with 43 completers, and the twelve-ingredient formulation precludes attribution to any single compound.
Key Points
- Flow-mediated dilation rose 2.9 points versus placebo over six months
- Systolic pressure fell 6.1 mmHg; arterial stiffness dropped 1.18 m/s
- Lipids unchanged; small sample, no washout, twelve ingredients untangled
Longevity Analysis
Vascular endothelium registers the cumulative burden of metabolic, inflammatory and oxidative load years before clinical events appear, which makes flow-mediated dilation and pulse wave velocity among the more honest readouts available for tracking biological rather than chronological aging. The magnitude of change here occurred in participants whose vascular measures already fell within normal ranges, suggesting that functional reserve in circulation remains modifiable even absent disease. Interpretation requires discipline: with measurements taken roughly 24 hours after the final dose and no washout period, the distinction between sustained arterial remodeling and an acute, recurring vasodilatory effect remains unresolved — a difference that matters considerably for anyone deciding how long to sustain the protocol.
Original published by Longevity.Technology, by Eleanor Garth.